Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The Final Frontier - Online Remote Trading -- Ignore unavailable to you. Want to Upgrade?

To: Ira Player who wrote (3973)	5/5/1998 2:02:00 PM
From: Leman	Respond to of 12617

HYALF going back HYALF looking to merge or be bought out from the april 17 release Consistent with the short term action plan announced on January 20, 1998, Hyal continues to work closely with investment bankers, Dresdner Kleinwort Benson, to evaluate all options to enhance shareholder value, which may include Hyal's merger or sale. As well Hyal continues its efforts to license those product candidates closest to market or most likely to be licensed over the next 12 months. Hyal believes that the agreement reached with the debenture holders will assist in the evaluation of these options. Hyal is engaged in research and product development utilizing its two unique platforms for drug delivery, HIT(TM) (Hyaluronan Induced Targeting) technology and HILT(TM) (Hyaluronan Improved Liposome Technology). The Corporation's business strategy is to commercialize its developments by outlicensing to other pharmaceutical companies.